13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001442756
Total reported value
$1.2B
$1.2B
70 檔
39.3%
As reported in its official Q3 2025 Form 13F filing, PFM Health Sciences, LP's tracked investment portfolio stood at $1.2B with 70 total positions.
PFM Health Sciences, LP executed strategic sector rebalancing during Q3 2025, establishing 34 new positions while fully exiting 29 holdings and trimming 25 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 13.21% | -1.48% | -16.00% | |
| 2 | THC | Tenet Healthcare CORP | Stock-Healthcare | 7.21% | -4.83% | -7.53% | |
| 3 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 5.53% | -5.30% | EXIT | |
| 4 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 4.95% | +0.54% | +9.78% | |
| 5 | MCK | Mckesson CORP | Stock-Healthcare | 4.30% | — | — | |
| 6 | PEN | Penumbra Inc | Stock-Healthcare | 3.80% | -2.56% | +17.34% | |
| 7 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.08% | -4.03% | +162.84% | |
| 8 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.66% | — | -13.00% | |
| 9 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.28% | +0.08% | -2.85% | |
| 10 | HUM | Humana Inc | Stock-Healthcare | 2.27% | +3.22% | NEW | |
| 11 | ASND | Ascendis Pharma A/S | Stock-Other | 2.22% | -3.64% | EXIT | |
| 12 | HCA | Hca Healthcare Inc | Stock-Healthcare | 2.16% | -0.49% | -9.02% | |
| 13 | CVS | Cvs Health CORP | Stock-Healthcare | 2.01% | +1.22% | NEW | |
| 14 | COR | Cencora Inc | Stock-Healthcare | 1.93% | +0.86% | NEW | |
| 15 | OM | Outset Medical Inc | Stock-Other | 1.88% | +0.01% | +3.92% | |
| 16 | UHS | Universal Health Services-b | Stock-Healthcare | 1.83% | — | — | |
| 17 | ICLR | ICON Public Limited Company | Stock-Healthcare | 1.80% | +1.45% | +51.60% | |
| 18 | CNC | Centene CORP | Stock-Healthcare | 1.58% | +1.07% | — | |
| 19 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.53% | +1.40% | NEW | |
| 20 | ELV | Elevance Health Inc | Stock-Healthcare | 1.51% | — | — | |
| 21 | NTRA | Natera Inc | Stock-Healthcare | 1.43% | -0.58% | +14.17% | |
| 22 | ADMA | Adma Biologics Inc | Stock-Healthcare | 1.33% | — | — | |
| 23 | NEO | Neogenomics Inc | Stock-Healthcare | 1.31% | -1.21% | EXIT | |
| 24 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.31% | -0.13% | -37.30% | |
| 25 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.27% | -0.76% | EXIT | |
| 26 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.24% | -1.91% | EXIT | |
| 27 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | Bond | 1.21% | -1.54% | EXIT | |
| 28 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 1.19% | +0.75% | +11.65% | |
| 29 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.19% | +1.05% | — | |
| 30 | VERA | Vera Therapeutics Inc | Stock-Other | 1.15% | +0.19% | — | |
| 31 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.13% | — | — | |
| 32 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 1.09% | — | +23.83% | |
| 33 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 1.05% | — | — | |
| 34 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 1.04% | — | -58.59% | |
| 35 | VEEV | Veeva Systems Inc-class A | Stock-Healthcare | 0.95% | — | — | |
| 36 | ✓ | Merus N V | Stock-Other | 0.95% | — | -28.90% | |
| 37 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.91% | — | -6.80% | |
| 38 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.86% | — | — | |
| 39 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 0.86% | +0.67% | NEW | |
| 40 | CMPS | Compass Pathways PLC | Stock-Other | 0.73% | -0.39% | -6.54% | |
| 41 | WAT | Waters CORP | Stock-Healthcare | 0.71% | +0.85% | -28.63% | |
| 42 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.66% | — | — | |
| 43 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.62% | +0.64% | -1.89% | |
| 44 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.62% | +0.50% | +346.50% | |
| 45 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 0.55% | — | -71.20% | |
| 46 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.52% | +0.54% | NEW | |
| 47 | CGON | Cg Oncology Inc | Stock-Other | 0.49% | -0.24% | — | |
| 48 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.46% | +0.04% | -40.44% | |
| 49 | COO | Cooper Cos Inc/the | Stock-Healthcare | 0.39% | +0.25% | — | |
| 50 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.37% | -0.11% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | THC | Tenet Healthcare CORP | +2.4% | -7.53% | Trim |
| 2 | ICLR | ICON Public Limited Company | +1.3% | +51.60% | Add |
| 3 | HUM | Humana Inc | +1.1% | +3.78% | Add |
| 4 | CNC | Centene CORP | +1% | — | Add |
| 5 | NEO | Neogenomics Inc | +0.9% | +186.81% | Add |
| 6 | CMPS | Compass Pathways PLC | +0.6% | -6.54% | Add |
| 7 | 260 | Centessa Pharmaceuticals-adr | +0.6% | +93.12% | Add |
| 8 | PEN | Penumbra Inc | +0.6% | +17.34% | Add |
| 9 | OM | Outset Medical Inc | +0.5% | +3.92% | Add |
| 10 | CVS | Cvs Health CORP | +0.5% | -27.63% | Add |
| 11 | OSCR | Oscar Health Inc - Class A | +0.4% | +11.65% | Trim |
| 12 | EW | Edwards Lifesciences CORP | +0.3% | -2.85% | Add |
| 13 | AMLX | Amylyx Pharmaceuticals Inc | +0.3% | -40.44% | Trim |
| 14 | INDV | Indivior Pharmaceuticals, Inc. | +0.2% | -58.59% | Trim |
| 15 | AXSM | Axsome Therapeutics Inc | +0.2% | +9.78% | Trim |
| 16 | HCA | Hca Healthcare Inc | +0.2% | -9.02% | Trim |
| 17 | GPCR | Structure Therapeutics Inc | +0.2% | +103.33% | Add |
| 18 | INBX | Inhibrx Biosciences Inc | +0.2% | -1.89% | Trim |
| 19 | ASND | Ascendis Pharma A/S | +0.1% | -34.47% | Trim |
| 20 | CRBU | Caribou Biosciences Inc | +0.1% | — | Trim |
| 21 | HOWL | Werewolf Therapeutics Inc | -0.1% | — | Trim |
| 22 | PRAX | Praxis Precision Medicines I | -0.2% | -28.49% | Trim |
| 23 | QURE | uniQure N.V. | -0.3% | -73.41% | Trim |
| 24 | UHS | Universal Health Services-b | -0.3% | — | Trim |
| 25 | AZNN | Astrazeneca Plc-spons Adr | -0.4% | — | Trim |
| 26 | MCK | Mckesson CORP | -0.5% | — | Trim |
| 27 | SNDX | Syndax Pharmaceuticals Inc | -0.5% | — | Trim |
| 28 | WAT | Waters CORP | -0.7% | -28.63% | Trim |
| 29 | ISRG | Intuitive Surgical Inc | -0.7% | -13.00% | Trim |
| 30 | TMO | Thermo Fisher Scientific Inc | -0.7% | — | Trim |
| 31 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | -0.8% | -49.93% | Trim |
| 32 | BBIO | Bridgebio Pharma Inc | -1% | -37.30% | Trim |
| 33 | ELV | Elevance Health Inc | -1.3% | — | Trim |
| 34 | SLNOEUR | Soleno Therapeutics Inc | -1.8% | -40.23% | Trim |
| 35 | ARGX | Argenx Se - Adr | -2.6% | -11.52% | Trim |
| 36 | LLY | Eli Lilly & Co | -3.2% | -16.00% | Trim |
| 37 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 38 | ABBV | Abbvie Inc | — | EXIT | Sold out |
| 39 | XLV | Ss Health Care Select Sector | — | EXIT | Sold out |
| 40 | VRTX | Vertex Pharmaceuticals Inc | — | EXIT | Sold out |
| 41 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 42 | COR | Cencora Inc | — | NEW | New buy |
| 43 | ALNY | Alnylam Pharmaceuticals Inc | — | EXIT | Sold out |
| 44 | MOH | Molina Healthcare Inc | — | EXIT | Sold out |
| 45 | DHR | Danaher CORP | — | EXIT | Sold out |
| 46 | BDX | Becton Dickinson And Co | — | EXIT | Sold out |
| 47 | MRK | Merck & Co. Inc. | — | NEW | New buy |
| 48 | IQV | Iqvia Holdings Inc | — | EXIT | Sold out |
| 49 | UNH | Unitedhealth Group Inc | — | EXIT | Sold out |
| 50 | NTRA | Natera Inc | — | NEW | New buy |
According to official SEC Form 13F filings, PFM Health Sciences, LP reported a total U.S. public equity portfolio value of $1.2B across 70 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, THC, XBI) accounted for 39.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
XBI
市值: $71.9M
Top Position Liquidated / Trimmed
ABBV
前期市值: $69.5M
During Q3 2025, PFM Health Sciences, LP's top holdings by market value included LLY (13.2%)、THC (7.2%)、XBI (5.5%). The largest single position, LLY, represented 13.2% of total portfolio value.
In Q3 2025, PFM Health Sciences, LP made 99 total portfolio adjustments, initiating 34 new buys, adding to 11 positions, trimming 25 holdings, and fully liquidating 29 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.